Autocrine VEGF mediates the antiapoptotic effect of CD154 and CLL cells

Leukemia

Volumn 19, Issue 4, 2005, Pages 524-530

  Farahani, Mosavar ^a   Treweeke, A T ^a   Toh, C H ^a   Till, K J ^a   Harris, R J ^a   Cawley, J C ^a   Zuzel, M ^a   Chen, H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CD154; CLL; VEGF

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTRALIZING ANTIBODY; SEMAXANIB; SURVIVIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

EID: 17144430972     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403631     Document Type: Article

References (50)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-1057.
2. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol 2000; 7: 223-234.
3. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 11-18.
4. Guipaud O, Deriano L, Salin H, Vallat L, Sabatier L, Merle-Beral H et al. B-cell chronic lymphocytic leukaemia: a polymorphic family unified by genomic features. Lancet Oncol 2003; 4: 505-514.
5. Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96: 3181-3187.
6. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16: 911-919.
7. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107: 605-610.
8. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001; 7: 795-799.
9. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000; 14: 1414-1418.
10. Alon T, Hemo I, Itin A, Péer J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-1028.
11. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904-1913.
12. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958.
13. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104: 788-794.
14. Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K et al. Etk/Bmx transactivates VEGFR2 and recruits phosphatidylinositol 3-kinase to mediate TNF-induced angiogenic pathway. J Biol Chem 2003; 278 51267-51276.
15. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881-922.
16. Schattner EJ. CD40 ligand in CLL pathogenesis and therapy. Leukemia Lymphoma 2000; 37: 461-472.
17. van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996; 61: 1-77.
18. Melter M, Reinders ME, Sho M, Pal S, Geehan C, Denton MD et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000; 96: 3801-3808.
19. Cho CS, Cho ML, Min SY, Kim WU, Min DJ, Lee SS et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 2000; 164: 5055-5061.
20. Tai YT, Podar K, Gupta D, Lin B, Young G, Akiyama M et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002; 99 1419-1427.
21. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997; 97: 409-417.
22. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 990-995.
23. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200-2206.
24. Grdisa M. Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leukemia Res 2003; 27: 951-956.
25. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995; 181: 1661-1672.
26. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270: 14255-14258.
27. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783.
28. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y et al. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 2002; 1 295-302.
29. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004; 103: 3883-3889.
30. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
31. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276: 7614-7620.
32. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-25654.
33. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999; 18: 363-374.
34. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015-4023.
35. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188-4197.
36. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002; 73 237-243.
37. Abeyama K, Eng W, Jester JV, Vink AA, Edelbaum D, Cockerell CJ et al. A role for NF-kappaB-dependent gene transactivation in sunburn. J Clin Invest 2000; 105: 1751-1759.
38. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003; 116: 665-674.
39. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
40. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-13316.
41. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264: 781-788.
42. Reinders ME, Sho M, Robertson SW, Geehan CS, Briscoe DM. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 2003; 171: 1534-1541.
43. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999; 48: 1131-1137.
44. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-1232.
45. Dikov MM, Oyama T, Cheng P, Takahashi T, Takahashi K, Sepetavec T et al. Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells. Cancer Res 2001; 61: 2015-2021.
46. Dadgostar H, Zarnegar B, Hoffmann A, Qin XF, Truong U, Rao G et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA 2002; 99: 1497-1502.
47. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis 2003; 8: 45-53.
48. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997; 272: 32521-32527.
49. Aramoto H, Breslin JW, Pappas PJ, Hobson RW, Duran WN. Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. Am J Physiol Heart Circ Physiol 2004; 287: H1590-H1598.
50. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995-1004.